Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated–neutrophil elastase aggregates
Ramesh C. Nayak, Sana Emberesh, Lisa R. Trump, Ashley M. Wellendorf, Abhishek K. Singh, Brice Korkmaz, Marshall S. Horwitz, Kasiani C. Myers, Theodosia A. Kalfa, Carolyn M. Lutzko, Jose A. Cancelas
Ramesh C. Nayak, Sana Emberesh, Lisa R. Trump, Ashley M. Wellendorf, Abhishek K. Singh, Brice Korkmaz, Marshall S. Horwitz, Kasiani C. Myers, Theodosia A. Kalfa, Carolyn M. Lutzko, Jose A. Cancelas
View: Text | PDF
Research Article Hematology

G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated–neutrophil elastase aggregates

  • Text
  • PDF
Abstract

Severe congenital neutropenia (SCN) is frequently associated with dominant point mutations in ELANE, the gene encoding neutrophil elastase (NE). Chronic administration of granulocyte colony–stimulating factor (G-CSF) is a first-line treatment of ELANE-mutant (ELANEmut) SCN. However, some ELANEmut patients, including patients with ELANE start codon mutations, do not respond to G-CSF. Here, through directed granulopoiesis of gene-edited isogenic normal and patient-derived iPSCs, we demonstrate that ELANE start codon mutations suffice to induce G-CSF–resistant granulocytic precursor cell death and refractory SCN. ELANE start codon–mutated neutrophil precursors express predominantly nuclear N-terminally truncated alternate NE. Unlike G-CSF–sensitive ELANE mutations that induce endoplasmic reticulum and unfolded protein response stress, we found that the mutation of the ELANE translation initiation codon resulted in NE aggregates and activated proapoptotic aggrephagy, as determined by downregulated BAG1 expression, decreased BAG1/BAG3 ratio, NE colocalization with BAG3, and localized expression of autophagic LC3B. We found that SERF1, an RNA-chaperone protein, known to localize in misfolded protein aggregates in neurodegenerative diseases, was highly upregulated and interacted with cytoplasmic NE of mutant neutrophil precursors. Silencing of SERF1 enhanced survival and differentiation of iPSC-derived neutrophil precursors, restoring their responsiveness to G-CSF. These observations provide a mechanistic insight into G-CSF–resistant ELANEmut SCN, revealing targets for therapeutic intervention.

Authors

Ramesh C. Nayak, Sana Emberesh, Lisa R. Trump, Ashley M. Wellendorf, Abhishek K. Singh, Brice Korkmaz, Marshall S. Horwitz, Kasiani C. Myers, Theodosia A. Kalfa, Carolyn M. Lutzko, Jose A. Cancelas

×

Figure 3

Expression of SERF1, an RNA binding chaperone, is upregulated and interacts with NE aggregates in ELANE translation initiation codon–mutant neutrophil precursors.

Options: View larger image (or click on image) Download as PowerPoint
Expression of SERF1, an RNA binding chaperone, is upregulated and intera...
(A) Representative immunoblots of SERF1A and SERF1B in normal, GTG-KI, GTG-P1, and GTG-C neutrophil precursors. SERF1A, but not SERF1B, expression is upregulated in ELANE translation initiation–mutant neutrophil precursors. (B) Representative Western blots of SERF1A and SERF1B in healthy donor (normal) and ELANEEX-3 mutant (I118N, Q97P) iPSC–derived neutrophil precursors. SERF1A expression is marginally reduced in ELANEEX-3 mutant SCN. (C and D) Representative confocal microscopic images of NE and SERF1 (C) and MFIs (D) of SERF1A in normal, GTG-KI, GTG-P1, and GTG-C neutrophil precursors. (E) Quantification of SERF1 cytoplasmic expression in normal, GTG-KI, GTG-P1, and GTG-C neutrophil precursors. Increased SERF1 expression is associated with translocation to cytoplasm. (F and G) Representative confocal images (F) and MFIs (G) of PLA signal between SERF1 and NE normal, GTG-KI, GTG-P1, and GTG-C neutrophil precursors. Scale bars: 10 μm. The MFIs of more than 10 cells from 2 independent experiments were quantified. Data are presented as individual data and mean ± standard deviation of 2 or 3 replicates per experiment and a minimum of 2 independent experiments. Differences between groups were evaluated using 1-way ANOVA. **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts